Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HMPL-011 tablets
HMPL-011 · 1 trial · 1 indication
Peak Plasma Concentration (Cmax) of HMPL-011 tablets (600 mg tablet X 2) and capsules (200 mg capsule X 6) in fasted States.
Peak Plasma Concentration (Cmax) of HMPL-011 tablets (600 mg tablet X 2) and capsules (200 mg capsule X 6) in fed States.
Steady State concentration of HMPL-011 will be caculated based on Ctrough
Area under the plasma concentration versus time curve (AUC) of HMPL-011 tablets (600 mg tablet X 2) and capsules (200 mg capsule X 6) in fed States.
Area under the plasma concentration versus time curve (AUC) of HMPL-011 tablets (600 mg tablet X 2) and capsules (200 mg capsule X 6) in fasted States.
| Arm | Type | Description |
|---|---|---|
| HMPL-011 tablets | ACTIVE_COMPARATOR | A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2) |
| HMPL-011 capsules | ACTIVE_COMPARATOR | A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6) |
| Name | Type | Description |
|---|---|---|
| HMPL-011 tablets | DRUG | Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance. |
| HMPL-011 capsules | DRUG | Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance. |
Inclusion Criteria: Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the study: * Healthy adult male and female subjects, 18-70 years of age, inclusive, at the time of signing the informed consent; * Body weight ≥ 50 kg and body mass index (BMI) wit...
HMPL-011 is an investigational small molecule being studied for inflammatory bowel diseases, a group of gastrointestinal conditions. It has been evaluated in a Phase 1 clinical trial in healthy male volunteers. HMPL-011 is not approved for any indication and remains in clinical development.
HMPL-011 is developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is the sponsor of the clinical program for this small molecule candidate in inflammatory bowel diseases.
HMPL-011 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The program has enrolled 24 participants in total and remains investigational, meaning it is not approved for commercial use.
HMPL-011 has been studied in one clinical trial, NCT03860532, titled Phase I Clinical Trial in Healthy Male Volunteers. The trial was a completed Phase 1 study with 24 enrolled participants, using a randomized, double-blind, active-controlled design in healthy volunteers.
Yes, HMPL-011 tablets is an alternative name for HMPL-011, the investigational small molecule developed by HUTCHMED (China) Limited for inflammatory bowel diseases. Both names refer to the same Phase 1 drug candidate.